Under the terms of the agreement, Valneva Sweden will provide analytical services, develop process scale-up and produce GMP clinical trial material to support the development of new immunotherapies based on HOOKIPA’s Vaxwave®* and TheraT®* arenavirus vector- technologies.In return, Valneva will receive fixed and success-based service fees. The agreement may be extended beyond three years.
Janet Hoogstraate, Chairman of Valneva Sweden, commented, “We are excited to collaborate and support HOOKIPA in its innovative development of novel immunotherapeutics to help overcome infectious diseases and cancers. This collaboration is a great recognition of Valneva’s strong technical and industrialization capabilities. Our dedicated Swedish unit has an excellent track record in development and clinical manufacturing.”
Joern Aldag, Chief Executive Officer of HOOKIPA, added, “The collaboration with Valneva will give us access to a dedicated GMP facility and qualified workforce for the manufacture of clinical trial material according to our specific needs. It emphasizes our strategy to secure sufficient manufacturing capacity, reduce cycle times and increase the robustness and consistency of the process. We look forward to working with Valneva’s great team.”
About Valneva SE
Valneva is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including a unique vaccine against Lyme disease. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with over 450 employees. More information is available at www.valneva.com.
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system. Our proprietary arenavirus-based technologies, Vaxwave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both, Vaxwave® and TheraT®, are designed to allow for repeat administration while maintaining an immune response. TheraT®* has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. Our “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system.
We have successfully completed a Phase 1 trial of a Vaxwave®-based prophylactic vaccine to protect against cytomegalovirus infection. We have initiated enrollment for a Phase 2 trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. To expand our infectious disease portfolio, we have entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. We are building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.
Find out more about HOOKIPA online at www.hookipapharma.com.